AstraZeneca says it takes China investigation very seriously'
AstraZeneca is cooperating with Chinese authorities amidst investigations into alleged illegal importation of cancer drugs.
China detains five AstraZeneca staff over data privacy and import breaches'
AstraZeneca employees are under investigation for potential data privacy breaches and the import of unauthorized cancer medications in China.
AstraZeneca says it's taking China's investigations into fraud, illegal drug importation and data collection 'very seriously'
AstraZeneca is cooperating with Chinese investigations into potential illegal activities, emphasizing its commitment to the Chinese market and innovative medicines.
AstraZeneca's drive for China dominance in focus as chief probed
AstraZeneca's growth in China faces scrutiny due to an investigation of aggressive sales tactics, impacting its reputation and future operations in the market.
AstraZeneca says it takes China investigation very seriously'
AstraZeneca is cooperating with Chinese authorities amidst investigations into alleged illegal importation of cancer drugs.
China detains five AstraZeneca staff over data privacy and import breaches'
AstraZeneca employees are under investigation for potential data privacy breaches and the import of unauthorized cancer medications in China.
AstraZeneca says it's taking China's investigations into fraud, illegal drug importation and data collection 'very seriously'
AstraZeneca is cooperating with Chinese investigations into potential illegal activities, emphasizing its commitment to the Chinese market and innovative medicines.
AstraZeneca's drive for China dominance in focus as chief probed
AstraZeneca's growth in China faces scrutiny due to an investigation of aggressive sales tactics, impacting its reputation and future operations in the market.
Is the system letting down people who were harmed by Covid vaccines?
The benefits of UK-recommended vaccines, including Covid vaccines, significantly outweigh the risks, despite some serious side effects experienced by a small number of individuals.
AstraZeneca withdraws Covid-19 Vaccine
The marketing authorization for Astra's vaccine Vaxzevria was withdrawn in the EU, not due to safety concerns, but because it's no longer being manufactured or supplied.
Is the system letting down people who were harmed by Covid vaccines?
The benefits of UK-recommended vaccines, including Covid vaccines, significantly outweigh the risks, despite some serious side effects experienced by a small number of individuals.
AstraZeneca withdraws Covid-19 Vaccine
The marketing authorization for Astra's vaccine Vaxzevria was withdrawn in the EU, not due to safety concerns, but because it's no longer being manufactured or supplied.
An FDA Ruling Could Make Nasal Vaccines Much More Widespread
The FDA has approved the FluMist nasal vaccine for home use, enhancing convenience and accessibility for flu vaccinations.
AstraZeneca's 450 million vaccine plant at risk as government reconsiders financial backing
The Treasury is in talks with AstraZeneca regarding a £450 million vaccine facility, but funding support is significantly reduced, raising concerns about investment viability.
AstraZeneca has withdrawn its Covid vaccine globally due to rare blood clot risks, despite saving over 6.5 million lives and being recognized for its role in ending the pandemic.
Big Pharma is losing its fight to avoid prescription drug price negotiations
The federal court rejected AstraZeneca's claim on prescription drug price negotiations under the 2022 IRA.
The ruling impacts 10 Medicare Part D-covered prescriptions and aims to set fair prices for these drugs.
AstraZeneca Loses Lawsuit Challenging Drug Price Negotiation by Medicare
AstraZeneca lost lawsuit on Medicare's drug price negotiation program.
Farxiga among the first 10 drugs for negotiation, impacting $50 billion Medicare costs.
AstraZeneca turns to AI for cancer antibody research
AstraZeneca has partnered with Absci to use AI to research antibodies for cancer treatment.
AstraZeneca will invest $247 million in AI-backed cancer research over multiple years.
AstraZeneca bets $247M AI can create cancer antibody
Pharma giant AstraZeneca has signed a $247 million deal with Absci to develop an antibody for fighting cancer.
Absci's AI model is designed to create new and improved antibody therapeutics, including for previously untreatable diseases.